Key result
Aspirin reduced the risk of non-fatal myocardial infarction overall (RR 0.72), but efficacy varied significantly by gender mix, with predominantly male trials showing a 38% reduction while predominantly female trials showed no significant benefit.
Why the study?
Does aspirin therapy reduce fatal and non-fatal myocardial infarction in primary and secondary cardiovascular prevention populations, and is this effect modified by gender?
Meta-Analysis (n=113,494)
Does aspirin therapy reduce fatal and non-fatal myocardial infarction in primary and secondary cardiovascular prevention populations, and is this effect modified by gender?
Relative Risk: 0.72 (95% CI 0.64–0.81)
p-value: p=<0.001
Gender accounts for a substantial proportion of the variability in aspirin's efficacy for reducing non-fatal MI, suggesting women may be less responsive to aspirin for MI prevention than men.
May warrant sex-specific aspirin counseling for MI prevention; confirms gender mix as major modifier in Level 1 evidence.
BACKGROUND: There is considerable variation in the effect of aspirin therapy reducing the risk of myocardial infarction (MI). Gender could be a potential explanatory factor for the variability. We conducted a systematic review and meta-analysis to determine whether gender mix might play a role in explaining the large variation of aspirin efficacy across primary and secondary MI prevention trials. METHODS: Randomized placebo-controlled clinical trials that examined the efficacy of aspirin therapy on MI were identified by using the PUBMED database (1966 to October 2006). Weighted linear regression technique was used to determine the relationship between log-transformed relative risk (RR) of MI and the percentage of male participants in each trial. The reciprocal of the standard error of the RR in each trial (1/SE) was used as the weight. RESULTS: A total of 23 trials (n = 113 494 participants) were identified. Overall, compared with placebo, aspirin reduced the risk of non-fatal MI (RR = 0.72, 95% confidence interval (CI) 0.64-0.81, p < 0.001) but not of fatal MI (RR = 0.88, 95% CI 0.75-1.03, p = 0.120). A total of 27% of the variation in the non-fatal MI results could be accounted for by considering the gender mix of the trials (p = 0.017). Trials that recruited predominantly men demonstrated the largest risk reduction in non-fatal MI (RR = 0.62, 95% CI 0.54-0.71), while trials that contained predominately women failed to demonstrate a significant risk reduction in non-fatal MI (RR = 0.87, 95% CI 0.71-1.06). CONCLUSION: Gender accounts for a substantial proportion of the variability in the efficacy of aspirin in reducing MI rates across these trials, and supports the notion that women might be less responsive to aspirin than men.
No takes yet. Share an insight, caveat, or question.
Yerman et al. (2007) conducted a meta-analysis in Myocardial infarction (n=113,494). Aspirin vs. Placebo was evaluated on Non-fatal myocardial infarction (RR 0.72, 95% CI 0.64-0.81, p=<0.001). Aspirin reduced the risk of non-fatal myocardial infarction overall (RR 0.72), but efficacy varied significantly by gender mix, with predominantly male trials showing a 38% reduction while predominantly female trials showed no significant benefit.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: